Fulcrum Therapeutics Inc

NASDAQ:FULC   4:00:00 PM EDT
9.44
-0.02 (-0.21%)
7:20:47 PM EDT: $9.00 -0.44 (-4.66%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)584.68M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.42 Million
Adjusted EPS-$0.44
See more estimates
10-Day MA$9.79
50-Day MA$9.26
200-Day MA$5.70
See more pivots

Fulcrum Therapeutics Inc Stock, NASDAQ:FULC

26 Landsdowne Street, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.651.8851
Number of Employees: 76

Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.